GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices ... to review patents listed in the FDA’s Orange Book — a registry of drugs approved by the ...

Having begun working together in December 2015, the partners are now ready to bring to market their custom digital sensor for GSK’s asthma and COPD inhaler, Ellipta. The sensor attaches to the ...

A year after British pharmaceutical giant, GlaxoSmithKline exited Nigeria and asthmatic patients who depended on its inhalers ...

The news followed an investigation by POLITICO’s E&E News into climate-friendly inhalers and how drug giants are developing them to undermine competition. The pharmaceutical giant AstraZeneca ...

Hannah Garden-Monheit, the director of the FTC's Office of Policy Planning, said in a statement that the decision was "important not only for lowering asthma inhaler costs, it also sets the stage ...

GlaxoSmithKline Pharmaceuticals Limited is ... Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company ...